A novel therapeutic approach for an existing drug reverses a condition in elderly patients who are at high risk for dementia due to Alzheimer’s disease, researchers at Johns Hopkins University found
The drug, commonly used to treat epilepsy, calms hyperactivity in the brain of patients with amnestic mild cognitive impairment (aMCI), a clinically recognized condition in which memory impairment is greater than expected for a person’s age and which greatly increases risk for Alzheimer’s dementia, according to the study published this week in NeuroImage: Clinical.
The findings validate the Johns Hopkins team’s initial conclusions, published three years ago in the journal Neuron. They also closely match the results in animal studies performed by the team and scientists elsewhere. Next, neuroscientist Michela Gallagher, the lead investigator, hopes the therapy will be tested in a large-scale, longer-term clinical trial.
Hippocampal over-activity is well-documented in patients with aMCI and its occurrence predicts further cognitive decline and progression to Alzheimer’s dementia, Gallagher said.
“What we’ve shown is that very low doses of the atypical antiepileptic levetiracetam reduces this over-activity,” Gallagher said. “At the same time, it improves memory performance on a task that depends on the hippocampus.”
The team studied 84 subjects — 17 of them were normal healthy aged participants and the rest had the symptoms of pre-dementia memory loss defined as aMCI. Everyone was over 55 years old, with an average age of about 70.
The subjects were given varying doses of the drug and also a placebo in a double-blind randomized trial. Researchers found low doses both improved memory performance and normalized the over-activity detected by functional magnetic resonance imaging that measures brain activity during a memory task. The ideal dosing found in this clinical study matched earlier preclinical studies in animal models.
“What we want to discover now, is whether treatment over a longer time will prevent further cognitive decline and delay or stop progression to Alzheimer’s dementia,” Gallagher said.
The Latest on: Alzheimer’s Disease
via Google News
The Latest on: Alzheimer’s Disease
- Drug shows promise in treating Alzheimer’son January 19, 2021 at 7:54 pm
Dr. Hazel Wiley with the Memory Disorder Center at Broward Health North said a small clinical trial showed a reduction in amyloid plaques in the brain, a key component of Alzheimer’s disease.
- General health checkups may detect early signs of Parkinson's diseaseon January 19, 2021 at 7:31 am
A research team led by Nagoya University in Japan has found that blood pressure, the hematocrit, and serum cholesterol levels change in patients with Parkinson's disease long before the onset of motor ...
- Eye tests predict which Parkinson's patients will develop dementiaon January 19, 2021 at 6:50 am
UK researchers have found that people with Parkinson's who performed worse on eye tests showed worse cognitive performance 18 months later.
- Alzheimer's: New research shows a leap forward in identifying neurons vulnerable to the diseaseon January 19, 2021 at 6:42 am
Alzheimer's disease is a devastating condition that is currently unstoppable and incurable. The main cause of the disease is the loss of neurons and other brain cells in the brain—also know as ...
- Visual arts: Painter responds to mother's battle with Alzheimer's disease with arton January 19, 2021 at 1:10 am
Susanne Dotson's show at Sarah Gormley Gallery in the Short North was inspired by her mother, who died Dec. 20.
- Researchers find potential biomarkers of Parkinson's diseaseon January 18, 2021 at 8:58 pm
A research team led by Nagoya University in Japan has found that blood pressure, the hematocrit (the percentage of red blood cells in blood), and serum cholesterol levels change in patients with ...
- Dementia: New blood test could be a game-changer for treating Alzheimer’s diseaseon January 18, 2021 at 4:01 pm
DEMENTIA research aims to stave off brain decline by identifying the risk as early on possible. New research published today suggests a new blood test could supercharge this effort.
- Global Alzheimer's Disease Diagnostics and...on January 18, 2021 at 2:00 pm
The "Alzheimer's Disease Diagnostics and Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been ...
- Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Programon January 18, 2021 at 6:00 am
Biohaven Pharmaceutical Holding Company Ltd. today announced that it has completed a focused analysis of the topline co-primary and key secondary data from its Phase 2/ 3 clinical trial of troriluzole ...
- Woman educates Black Marylanders on Alzheimer’s diseaseon January 17, 2021 at 11:02 am
Alzheimer’s disease can start with something as simple as misplacing items or having difficulty completing daily tasks.
via Bing News